FCR 3

Office of the President September 16, 2022

Members, Board of Trustees:

REQUEST TO AMEND THE EWA MARCINIAK, MD CHAIR IN MEDICINE SELECTION CRITERIA

<u>Recommendation</u>: that the Board of Trustees approve a request from the College of Medicine, Department of Internal Medicine, Division of Hematology and Markey Cancer Center (collectively referred to herein as the "College") to amend the selection criteria of the Ewa Marciniak, MD Chair in Medicine endowment to expand the scope of the Chairholder's research, teaching and clinical purpose to include oncology. The Chair will be housed within the College's Internal Medicine, Hematology, or Oncology Divisions within the Department of Internal Medicine and be selected by the Dean of the College of Medicine in conjunction with the Chair of Internal Medicine in collaboration with the Director of the Markey Cancer Center.

<u>Background</u>: In 2011, Dr. Ewa Marciniak and the University entered a Charitable Gift Agreement (the "Agreement") to establish the parameters of the Dr. Ewa Marciniak, MD Chair in Medicine endowment (the "Chair"). The Agreement contained selection criteria limiting the Chairholder's academic and clinical focus to benign hematology and assisting with managing adult patients with bleeding. Dr. Marciniak designated a gift through her estate to fund the Chair. Following her death on December 2, 2015, and consistent with the authority conferred by the Agreement, the Board of Trustees (the "Board") approved the establishment of the Chair without any changes to the selection criteria set forth in the Agreement and accepted the gift by FCR 4 dated May 3, 2016.

Since 2016, advances in the field of benign hematology, a medical science concentrating on undiagnosed and benign illnesses affecting blood and blood-forming organs, have reduced the patient population being treated for such blood disorders at the university. Further, in response to the acute needs in related fields studying blood illnesses generally (hematology) and blood cancers like leukemia (oncology), there has been a national shift toward research in these areas. These changes have greatly reduced the number of clinicians meeting the Board approved selection criteria. The present market value of the Chair has grown to over \$3.5 million.

The Chair selection criteria approved by the Board now imposes a hardship on the College. The College requests the Board approve an amendment to the Chair selection criteria. Specifically, the College requests an expansion of the selection criteria allowing the Chairholder to have an academic, research and clinical concentration in hematology

and oncology, and assist with managing adult patients in the area of blood related cancers. This Amendment better addresses the status of hematologic research in the United States, will enable the College to recruit a preeminent scholar to chair the Hematology and Oncology Divisions at the university and support the critical expansion of the Markey Cancer Center. Furthermore, this amendment will allow Dr. Marciniak's gift to continue the tremendous impact in service to Kentuckians and advancements to the cutting-edge science of which she had devoted her esteemed medical practice.